A 59-year-old woman with gastroesophageal reflux disease and Barrett esophagus

JAMA

Volumn 289, Issue 4, 2003, Pages 466-475

  Spechler, Stuart Jon ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; RANITIDINE; SUCRALFATE;

ADENOCARCINOMA; ADULT; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CASE REPORT; CLINICAL FEATURE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DYSPLASIA; ENDOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFESTYLE; PRIORITY JOURNAL; STOMACH FUNDOPLICATION;

EID: 0037460160     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.4.466     Document Type: Conference Paper

References (90)

1. Kahrilas PJ. Gastroesophageal reflux disease. JAMA. 1996;276:983-988.
2. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton U III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
3. Jaroff L. Fire in the belly, money in the bank. Time. November 6, 1995.
4. Spechler SJ. Epidemiology and natural history of gastro-oesophageaf reflux disease. Digestion. 1992;51(suppl 1):24-29.
5. Baron TH, Richter JE. Gastroesophageal reflux disease in pregnancy. Gastroenterol Clin North Am, 1992;21:777-791.
6. Shaker R, Castell DO, Schoenfeld PS, Spechier SJ. Nighttime heartburn is an underappreciated clinical problem that impacts sleep and daytime function. Gastroenterology. 2001;120(suppl 1):A420.
7. Farup C, Kleinman L, Sloan S, et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001;161:45-52.
8. Spechler SJ. Barrett's esophagus. N Engl J Med. 2002;346:836-842.
9. Lagergren J, Bergström R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340:825-831.
10. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
11. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000; 119:333-338.
12. Richter JE. Chest pain and gastroesophageal reflux disease. J Clin Gastroenterol. 2000;30(3 suppl):S39-S41.
13. Jailwala JA, Shaker R. Oral and pharyngeal complications of gastroesophageal reflux disease: globus, dental erosions, and chronic sinusitis. J Clin Gastroenterol. 2000;30(3 suppl):S35-S38.
14. Harding SM, Richter JE. The role of gastroesophageal reflux in chronic cough and asthma. Chest. 1997;111:1389-1402.
15. Ormseth EJ, Wong RKH. Reflux laryngitis: pathophysiology, diagnosis and management. Am J Gastroenterol. 1999;94:2812-2817.
16. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am. 1997;26:487-494.
17. Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol. 1998;93:1816-1822.
18. Sonnenberg A, Massey BT, Jacobsen SJ. Hospital discharges resulting from esophagitis among medicare beneficiaries. Dig Dis Sci. 1994;39:183-188.
19. Spechler SJ, Jain SK, Tendler DA, Parker RA, Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:1795-1800.
20. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacterpylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998;58:588-590.
21. Graham DY, Yamaoka Y. H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter. 1998; 3:145-150.
22. Vaezi MF, Falk GW, Peek RM, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol. 2000;95:2206-2211.
23. Malfertheiner P, O'Connor JH, Genta RM, Unge P, Axon ATR. Symposium: Helicobacter pylori and clinical risks - focus on gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(suppl 3):1-10.
24. Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol. 1998;93:1800-1802.
25. DeVault KR, Castell DO, and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999;94:1434-1442.
26. Ott DJ. Gastroesophageal reflux disease. Radiol Clin North Am. 1994;32:1147-1166.
27. Armstrong D. Endoscopic evaluation of gastro-esophageal reflux disease. Yale J Biol Med. 1999;72:93-100.
28. Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med. 2000;160:1810-1816.
29. Sampliner RE and The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Gastroenterol. 2002;97:1888-1895.
30. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer. JAMA. 2002;287:1972-1981.
31. Devault KR, Castell DO for The Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med. 1995;155:2165-2173.
32. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798-1810.
33. Eggleston A, Wigerinck A, Huijghebaert S, Dubois D, Haycox A. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut. 1998;42:13-16.
34. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121:1095-1100.
35. Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16:261-273.
36. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983;28:559-563.
37. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000;14:669-690.
38. Orlando RC. Sucralfate therapy and reflux esophagitis: an overview. Am J Med. 1991;91(2A):123S-124S.
39. McCallum RW, Fink SM, Winnan GR, Avella J, Callachan C. Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial. Am J Gastroenterol. 1984;79:165-172.
40. Spechler SJ. Peptic ulcer disease and its complications. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal & Liver Disease. Philadelphia, Pa: Saunders; 2002:747-781.
41. Hansten PD. Drug interactions with antisecretory agents. Aliment Pharmacol Ther. 1991;5(suppl 1):121-128.
42. Wilder-Smith CH, Ernst T, Gennoni M, Zeyen B, Halter F, Merki HS. Tolerance to oral H2-receptor antagonists. Dig Dis Sci. 1990;35:976-983.
43. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575-583.
44. Richter JE, Kahrilas PJ, Johanson J, et al, for the Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001;96:656-665.
45. Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology. 1988;95:903-912.
46. Klinkenberg-Knol EC, Nelis F, Dent J, et al, and Long-Term Study Group. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661-669.
47. Smith PM, Kerr GD, Cockel R, et al, and the Restore Investigator Group. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology. 1994;107:1312-1318.
48. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93:763-767.
49. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998;12:1231-1234.
50. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology. 1998;115:1335-1339.
51. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625-632.
52. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis: a controlled double blind trial of their efficacy and safety. Gut. 1994;35:590-598.
53. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology. 1993;104:1356-1370.
54. Verdu E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut. 1994;35:455-460.
55. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018-1022.
56. Garcia Rodriguez LA, Ruigomez A. Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk? Epidemiology. 1997;8:571-574.
57. Marcuard SP, Albernaz L, Khazanie PG. Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med. 1994;120:211-215.
58. Dunnington GL, DeMeester TR. The outcome effect of adherence to operative principles of Nissen fundoplication by multiple surgeons. Am J Surg. 1993; 166:654-657.
59. Hinder RA, Libbey JS, Gorecki P, Bammer T. Antireflux surgery: indications, preoperative evaluation, and outcome. Gastroenterol Clin North Am. 1999;28:987-1005.
60. Spechler SJ for the Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. N Engl J Med. 1992;326:786-792.
61. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical treatments for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA. 2001;285:2331-2338.
62. Lundell L, Miettinen P, Myrvold HE, et al. Long-term management of gastrooesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol. 2000;12:879-887.
63. Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg. 2001;192:172-181.
64. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet. 1994;344:1533-1536.
65. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus: the need for standardization of the definition and of endoscopic criteria. Am J Gastroenterol. 1998;93:1033-1036.
66. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med. 2000; 132:612-620.
67. Cameron AJ. Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol Clin North Am. 1997;26:487-494.
68. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RKH. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology. 1999;116:277-285.
69. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med. 1999;130:883-890.
70. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology. 2002;123:461-467.
71. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26-33.
72. Ter RB, Castell DO. Gastroesophageal reflux disease in patients with columnar-lined esophagus. Gastroenterol Clin North Am. 1997;26:549-563.
73. Ouatu-Lascar R, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol. 1998;93:711-716.
74. Fitzgerald RC, Omary MB, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus: an ex vivo proliferation and differentiation model. J Clin Invest. 1996;98:2120-2128.
75. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology. 1999;117:327-335.
76. Souza RF, Shewmake K, Terada LS, Spechler SJ. Acid exposure activates the mitogen activated protein kinase pathways in Barrett's esophagus. Gastroenterology. 2002;122:299-307.
77. Fennerty MB, Triadafilopoulos G. Barrett's-related esophageal adenocarcinoma: is chemoprevention a potential option? Am J Gastroenterol. 2001;96:2302-2305.
78. Spechler SJ. Acid suppression therapy for Barrett's esophagus. Eur J Surg Suppl. 2001;586:78-81.
79. Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4:50-54.
80. Ye W, Chow WH, Lagergren J, Yin L, Nyren O. Risk of adenocarcinoma of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology. 2001;121:1286-1293.
81. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633-640.
82. Spechler SJ. Disputing dysplasia. Gastroenterology. 2001;120:1864-1868.
83. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol. 2000;95:3383-3387
84. Van den Boogert J, van Hillegersberg R, Siersema PD, de Bruin RWF, Tilanus HW. Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: a review. Am J Gastroenterol. 1999;94:1153-1160.
85. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999;49:1-7.
86. Davila ML, Keefe EB. Complications of gastrointestinal endoscopy. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Diseases: Pathophysiology/Diagnosis/Management. 7th ed. Philadelphia, Pa: Saunders; 2002:539-548.
87. Goy JA, Herold E, Jenkins PJ, Colman JC, Russell DM. "Open-access" endoscopy for general practitioners: experience of a private gastrointestinal clinic. Med J Aust. 1986;20:71-74.
88. Richter JE, Castell DO. Gastroesophageal reflux: pathogenesis, diagnosis, and therapy. Ann Intern Med. 1982;97:93-103.
89. Triadafilopoulos G, DiBaise JK, Nostrant TT, et al. The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the US open label trial. Gastrointest Endosc. 2002;55:149-156.
90. Filipi CJ, Lehman GA, Rothstein RI, et al. Transoral, flexible endoscopic suturing for treatment of GERD: a multicenter trial. Gastrointest Endosc. 2001;53:416-422.